Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer

Y Nakanishi, T Masuda, K Yamaguchi… - Respiratory …, 2019 - Elsevier
Background Approximately 5% of non-small cell lung cancer (NSCLC) patients develop
immune checkpoint inhibitor (ICI)-induced interstitial lung disease (ICI-ILD), 10% of whom …
被引用次数：101 相关文章

Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer

Y Nakanishi, T Masuda, K Yamaguchi… - Respiratory …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Approximately 5% of non-small cell lung cancer (NSCLC) patients develop
immune checkpoint inhibitor (ICI)-induced interstitial lung disease (ICI-ILD), 10% of whom …

Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.

Y Nakanishi, T Masuda, K Yamaguchi… - Respiratory …, 2019 - europepmc.org
BACKGROUND: Approximately 5% of non-small cell lung cancer (NSCLC) patients develop
immune checkpoint inhibitor (ICI)-induced interstitial lung disease (ICI-ILD), 10% of whom …

[引用][C] Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer

Y Nakanishi, T Masuda, K Yamaguchi… - Respiratory …, 2019 - cir.nii.ac.jp
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced
interstitial lung disease in non-small cell lung cancer | CiNii Research CiNii 国立情報学研究所 …